Bayer's Legal Landmark Meets Its Next Hurdle: A $7.25 Billion Settlement Vote

The U.S. Supreme Court handed Bayer a historic victory last Thursday, stripping thousands of Roundup lawsuits of their legal foundation in a 7-2 ruling. Shares of the Leverkusen-based conglomerate responded with a blistering 23% rally over seven sessions, closing Friday at €46.61. But the euphoria masks a precarious next act: a Missouri court hearing on July 9 will determine whether Bayer can finally lock in a $7.25 billion settlement that would cap the bulk of its remaining glyphosate liability.

At the heart of the Supreme Court decision was a clear jurisdictional line. The justices, in the case of Durnell versus Monsanto, ruled that state-law claims for missing cancer warnings on Roundup are preempted when the U.S. Environmental Protection Agency does not require such labels. Since the EPA continues to classify glyphosate as non-carcinogenic, the ruling effectively guts the most common accusation against Bayer’s herbicide. Analysts at Bank of America called it a decisive turning point.

Yet the legal win is incomplete. The massive class-action settlement, initially negotiated to cover future claims, still lacks final court approval. Federal Judge Henry E. Autrey remanded the case King v. Monsanto back to a Missouri state court in mid-June, leaving the agreement in limbo. The proposed payout structure calls for up to $7.25 billion in declining installments over a maximum of 21 years, and Bayer has already set aside €11.8 billion in provisions for litigation. Should the Missouri judge reject the deal or alter its terms, the recent rally would face immediate headwinds.

Should investors sell immediately? Or is it worth buying Bayer?

Balance Sheet Strain Persists

Despite the legal relief, Bayer’s finances remain under pressure. The group posted a negative free cash flow of €2.3 billion in the first quarter alone, and management expects total cash outflows of roughly €5 billion this year tied to existing lawsuits. Net debt stands at a towering €32.5 billion. The company’s revenue slipped to €45.6 billion last year as currency headwinds erased modest organic growth, while patent expirations continue to dent the pharmaceuticals segment.

The pharma division is not standing still. The FDA has approved Gadoquatran, a new contrast agent, and the European Medicines Agency is reviewing asundexian, an oral Factor XIa inhibitor. A Phase III trial showed a 26% reduction in stroke risk with no significant increase in bleeding. Analysts see peak sales potential exceeding €3 billion for the drug. Separately, Bayer has partnered with Iambic Therapeutics to use artificial intelligence in small-molecule drug discovery, aiming to slash the typical ten-year, $2.6 billion development timeline.

Chart Signals Caution

The stock’s breathtaking ascent has pushed the Relative Strength Index to 80.6, deep into overbought territory. Shares now trade just 7% below their 52-week high of €49.93 and sit 27.4% above the 200-day moving average. Technical analysts view consolidation after such a surge as a normal, healthy pause.

What Comes Next

CEO Bill Anderson has set a year-end target to substantially reduce U.S. legal risk. The Supreme Court ruling is a critical milestone, but it is not the finish line. The July 9 hearing in Missouri will test whether Bayer can finally close the chapter on the largest outstanding claims. If the settlement receives the green light, the company will have cleared away one of its heaviest overhangs. If it stalls, the negative cash flow leaves management scant room for setbacks. For now, the market is betting on resolution — but the next few weeks will determine whether that bet pays off.

Ad

Bayer Stock: New Analysis - 28 June

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

en | DE000BAY0017 | BAYERS | boerse | 69646963 |